Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Valeant Pharmaceuticals International Inc. CEO Michael Pearson is seen in one of the company’s laboratories in Laval. (Ryan Remiorz/THE CANADIAN PRESS)
Valeant Pharmaceuticals International Inc. CEO Michael Pearson is seen in one of the company’s laboratories in Laval. (Ryan Remiorz/THE CANADIAN PRESS)

Ukraine approves Valeant’s purchase of Obagi Add to ...

Valeant Pharmaceuticals International Inc. says Ukraine’s anti-monopoly committee has given its approval for the Montreal-based company to buy Obagi Medical Products Inc.

Valeant has offered $24 (U.S.) per share for Obagi or about $418-million.

The drug company said Wednesday it does not expect to further extend its offer beyond the current deadline of midnight Thursday night.

More Related to this Story

Valeant said earlier this week that it had cleared a U.S. regulatory hurdle, with the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

The company beat out German company Merz Pharma Group which had offered $22 per share, but dropped out of the bidding earlier this month.

Valeant, formerly Biovail Corp., develops, manufactures and sells a range of neurology, dermatology and branded generic drugs.

Follow us on Twitter: @GlobeBusiness

 
  • VRX-N
  • OMPI-Q
Live Discussion of VRX on StockTwits
More Discussion on VRX-N
Live Discussion of OMPI on StockTwits
More Discussion on OMPI-Q

Topics:

In the know

Most popular video »

Highlights

More from The Globe and Mail

Most Popular Stories